In this study we report on the establishment and characterization of a novel knock-in mouse model that is homozygous for the R51Q mutation in the sorting nexin 10 (SNX10) protein. This mutation leads to massive, early-onset, and widespread osteopetrosis in the mutant mice, similar to that observed in humans who are homozygous for this mutation. The diseased mice exhibit multiple additional characteristics of the corresponding human osteopetrosis, including missing and impacted teeth, occasional osteomyelitis, stunted growth, failure to thrive, and a significantly-reduced lifespan. The phenotype of homozygous R51Q SNX10 osteoclasts is unique and defines a novel form of ARO that combines both lack of bone-resorbing activity and reduced cell numbers in vivo. Furthermore, mutant osteoclasts grown on bone develop a giant cell morphology, reaching sizes that are up to three orders of magnitude larger than osteoclasts from wild-type or heterozygous mice. These large osteoclasts display poor survival in vitro, which may account for their fewer numbers in vivo. Electron microscopy studies indicate that homozygous mutant osteoclasts exhibit severely impaired ruffled borders and are incapable of resorbing bone, providing a clear cellular basis for the osteopetrotic phenotype. We propose that the R51Q SNX10 mutation directly causes osteoporosis by affecting both osteoclast formation and function.
Introduction
Formation and remodeling of bone requires the coordinated activities of two cell types; osteoblasts, which deposit new bone matrix, and osteoclasts (OCLs), which degrade it. OCLs are large, multi-nucleated phagocytic cells that are generated by fusion of monocyte-macrophage precursors in a process driven by the cytokines M-CSF and RANKL. OCLs adhere to mineralized tissue via podosomes, specialized adhesion structures that assemble into a sealing zone at the cell periphery, which confines the bone area that is being degraded. The cells then secrete from a specialized region of their ventral membrane, known as the ruffled border, proteases and protons, which degrade the protein and mineral components, respectively, of the bone in the resorption cavity (1) .
Proper balance between bone synthesis and degradation is critical for healthy bone homeostasis, and upsetting this balance by excessive or deficient OCL activity leads to skeletal disorders such as osteoporosis or osteopetrosis, respectively (1, 2) . Of particular relevance to this study is autosomal recessive osteopetrosis (ARO; infantile malignant osteopetrosis, IMO), a cluster of genetic disorders that is caused by failure of OCL-mediated bone resorption. ARO is a rare disease, with a global incidence of 1 in 250,000 live births, and is lethal unless treated in a timely manner by hematopoietic stem cell transplantation (HSCT) that enables production of functional osteoclasts (3, 4) . In most ARO cases OCLs are present but are non-functional ("osteoclast-rich ARO", (3)). Roughly two-thirds of these cases are caused by mutations in TCIRG1, which encodes the a3 subunit of the V0 domain of the ATP-dependent vacuolar proton pump of osteoclasts, or in CLCN7, which encodes chloride voltage-gated channel 7, a
Cl
-/H + antiporter, both of which are critical for acid secretion that is essential for bone resorption by
OCLs. Osteoclast-rich ARO can also arise due to mutations in OSTM1,which encodes the beta subunit of the Cl -/H + antiporter, and PLEKHM1, whose lysosome-associated protein product functions in vesicular trafficking (3) (4) (5) . Osteoclast-poor ARO, caused by an absence of OCLs, has been linked to mutations in TNFRSF11A or TNFSF11, which encode the TNF receptor superfamily member 11A
(RANK) or its ligand, RANKL, respectively. Both molecules are essential for differentiation of OCLs from their precursor monocytic cells (3, 4) .
Homozygosity for the R51Q mutation in Sorting Nexin 10 (SNX10) was shown recently to cause ARO due to inactive OCLs in patients from Palestinian clans (6) . Subsequent studies have revealed additional mutations in SNX10, including nonsense, mis-sense, and splicing defect mutations, that cause ARO in patients of diverse ethnic origins in Europe, North America and Asia. It is currently estimated that mutations in SNX10 account for 5% of ARO cases globally (4, 7, 8) . The specific symptoms of patients carrying distinct SNX10 mutations vary, but several symptoms are characteristic. These include early age of onset, significantly increased bone mass, anemia, hepatosplenomegaly, and impaired vision and hearing that are caused by gradual closure of skull foramina arising from reduced bone resorption.
Additional symptoms may include short stature, failure to thrive, thrombocytopenia, and absent or impacted teeth (6) (7) (8) .
SNX10 belongs to a family of over 30 related proteins that participate in the regulation of endosome sorting in cells. All SNX proteins contain a phosphatidylinositol-binding (PX) domain that enables them to interact with cellular membrane compartments (9) , but their exact biochemical functions are largely unknown. In addition to its N-terminal PX domain, SNX10 contains a C-terminal domain that is rich in serine residues and in negatively-charged amino acids. The function of this domain is unknown, but it appears to be required for vacuole formation in mammalian cells (10) . In osteoclasts SNX10 was reported to be associated with the endoplasmic reticulum and to be present in the nucleus (11) . The protein was also shown to be required for differentiation of RAW 264.7 cells into osteoclastlike cells and for their resorptive activity in vitro (11, 12) . SNX10 associates with the ATP-dependent vacuolar proton pump of OCLs (V-ATPase) and affects its function (13) , suggesting that SNX10 might be involved in the localization of the V-ATPase to the ruffled border in OCLs (4, 6, 8) .
Osteoclasts prepared in vitro from mononuclear leukocytes of R51Q SNX10 patients were few, grew poorly, and exhibited significantly reduced resorptive activity when cultured on mineral-coated substrates (6) . Cellular studies of patients carrying the distinct Vasterbotten frameshift mutation in SNX10 (c.212+1G>T, leading to premature termination of the protein (7)) indicated that OCLs prepared from these patients are two-to five-fold larger than cells derived from healthy individuals. The mutant
OCLs are non-functional, presumably due to impaired ruffled borders (7) . Global knock-down of the orthologous Snx10 gene in mice resulted in osteopetrosis, due to reduced activity of osteoclasts, and rickets, due to elevated stomach pH and reduced calcium resorption (14) . Mice in which Snx10 was specifically knocked-down in OCLs exhibited osteopetrosis without rickets; OCLs from these mice also exhibited impaired ruffled border structure and acidification ability, and were non-functional (14) .
Notably, all known mutations in SNX10 that are associated with ARO are located within the PX domain of the molecule, confirming its importance for osteoclast function. However, since the clinical manifestations of ARO induced by these mutations are variable (8), a deeper understanding of how distinct mutations affect osteoclast formation, structure, and resorption activity is needed.
In order to examine the specific consequences of the R51Q mutation in SNX10 in vivo, we generated R51Q SNX10 knock-in mice. We show here that homozygous R51Q SNX10 mice are severely osteopetrotic due to lack of OCL-mediated bone resorption. This and other aspects of the R51Q SNX10 mouse phenotype closely resemble the human R51Q SNX10 ARO phenotype, confirming the R51Q mutation as a causative factor for ARO. The cellular phenotype of these mice is, however, unique. R51Q SNX10 OCLs are both non-functional and less abundant in vivo indicating that, in contrast to other known mutations in SNX10 and in other proteins that lead to ARO, the R51Q mutation affects both the production and the function of these cells. Homozygous R51Q SNX10 OCLs grown on bone lack ruffled borders, which abolishes their activity, and are dramatically larger than their wild-type and heterozygous counterparts, which negatively impacts their stability and survival. The gigantic size of these cells
indicates that the size of OCLs is actively regulated by cellular proteins and that SNX10 plays an important role in this process, which is disrupted by the R51Q mutation.
Materials and Methods

Generation of R51Q SNX10 knock-in mice:
Mice carrying the R51Q mutation in SNX10 were constructed by CRISPR at The Weizmann Institute.
Candidate sgRNA sequences were selected from SNX10 genomic sequences using sgRNAScorer 2.0 (https://crispr.med.harvard.edu/sgRNAScorer/ ; (15) ) and the CRISPR design tool of the Zhang lab, MIT 
Human Studies
Retrospective blood calcium levels from R51Q SNX10 patients were obtained from their files at the Hadassah Medical Center. Researchers conducting this study were blinded to the identity of the patients.
Access to patient data was approved by the Ethics Committee of the Hadassah Medical Center and by the Institutional Review Board of The Weizmann Institute.
Primary mouse osteoclasts
Osteoclast precursors were isolated from spleens of mice aged 6-8 weeks. Spleens were washed very briefly with 70% ethanol and then in PBS, and mashed through a 70µM cell strainer into unsupplemented α-Minimal Eagle's Medium (α-MEM; Sigma, St. Louis, MO, USA). Following centrifugation, cells were resuspended for 1 minute in 1ml of red blood cell lysis buffer (Sigma), followed by addition of 10 ml unsupplemented α-MEM. Cells were seeded at a density of 5x10 6 cells/well (for +/+ or RQ/+) and 2.5x10 6 cells/well (RQ/RQ) in 6-well plates, or 2x10 6 cells/well (+/+ or RQ/+) and 1x10 6 cells/well (RQ/RQ) in 24-well plates. Cells were cultured in complete OCL medium (α-MEM supplemented with 10% fetal calf serum, 2 mM glutamine, 50 units/ml penicillin, and 50 g/ml streptomycin, as well as 20 ng/ml M-CSF (Peprotech, Rocky Hill, NJ, USA) and 20 ng/ml RANKL (R&D Systems, Minneapolis, MN, USA)). Cells were incubated at 37 °C in 5% CO2 for 5-7 days (day of seeding is counted as day 0) with daily changes of medium.
Culture of OCLs on bone fragments
Fragments of bovine femurs were sliced into 3X3X0.5mm slices with a low-speed diamond wheel saw, and were stored in 70% ethanol at 4°C until use. Prior to seeding, bone slices were sonicated for 10 min at 50-60 Hz, washed in 70% ethanol and in PBS, placed in 24-well plates (2-3 slices/well) and incubated in OCL medium (without cytokines) for 1hr at 37 °C in 5% CO2. Cells were prepared as above and cultured in complete OCL medium supplemented solely with 20 ng/ml M-CSF. When confluent, cells
were detached with Trypsin-EDTA and seeded at a density of 1x10 5 Cells/well in 24-well plates or on coverslips. Cells were then cultured in complete OCL medium that included 20 ng/ml M-CSF and 20 ng/ml RANKL, with changes of medium every 48-72 hours.
Analysis of OCLs grown on bone
OCLs grown on bone slices were stained for TRAP using the Leukocyte Acid Phosphatase kit (Sigma).
For actin staining, cells were permeabilized and fixed by incubating the slices in 0.5% Triton X-100/3%
PFA for 3 minutes, followed by fixation in 3% PFA for 20 minutes and washes in PBS. Cells were then exposed to TRITC-phalloidin (diluted 1:500) (Sigma) for 1 hour at room temperature. DNA was visualized by incubating the slices with Hoechst 33258 (diluted 1:3000) (Molecular Probes, Eugene, OR, USA) for 3 minutes, followed by washes in PBS. For size measurements, bone fragments with OCLs attached were collected for TRAP staining 14 (+/+ ) and 10 (RQ/RQ) days after the start of RANKL treatment due to the faster differentiation rate of RQ/RQ cells ( Fig 5A) . Cell size was measured using the ImageJ polygon tool. All multinucleated RQ/RQ cells present on two bone fragments were measured (n=280); due to their larger number, all multinucleated cells present in one field on each of two separate bone fragments were measured (n=353).
Primary mouse osteoblasts: Preparation, growth, and analysis of mineralization
Osteoblasts were prepared from calvarias of 5-day old pups and grown as described (16) . For osteogenic inductions cells were seeded in 10 cm plartes at 50,000 cells/ml and induced at no more than 80%
confluency the next day in culture medium (a-MEM, supplemented with 10% FCS, 100 units/ml penicillin, and 100 µg /ml streptomycin), supplemented with 100 µg/ml ascorbic acid and 1 mg/ml β-glycerophosphate, or left untreated as control. The medium was changed every 3-4 days.
After 7 days of culture early mineralization was assessed quantitatively by alkaline phosphatase (ALP) staining. ALP staining was assessed qualitatively by fixation of cells with 4% PFA and staining with Fast Violet B Salt and naphtol AS-MX phosphate alkaline solution (16) . Analysis of late mineralization was performed following fixation with 4% PFA and staining with 1% Alizarin Red (pH 4.2). Quantification was carried out by measuring absorbance at 570nm after dissolving the dye with 100mM cetylpyridinium chloride.
Histomorphometry, histology, and skeletal analyses
Calcein labeling: Mice were injected IP with 30 mg/kg body weight of calcein solution (10 mg/ml calcein in 0.15M NaCl/2% NaHCO3), on days 1 and 8. Mice were sacrificed on day 10; skin and internal organs were removed, and the mice were fixed in 4% paraformaldehyde/PBS for 3 days, and then kept in 70% ethanol until analyzed. Mice were analyzed prior to weaning at 20-25 days of age; both male and female mice from both R51Q SNX10 mouse lines were analyzed.
X-ray images of mouse skeletons were obtained using an MX20 Cabinet X-Ray system (Faxitron XRay, Lincolnshire, IL, USA) instrument using standard settings.
Micro-CT measurements were carried out with the SkyScan1176 µCT (Bruker, Billerica, MA, USA) using a 50µm aluminum filter, 9µm voxel size and a 1° rotation step. The software programs NRecon, Data Viewer, CTAn, CTVol (Bruker) were used for analysis. For tissue mineral density measurements the bones were rehydrated in PBS and phantoms of 0.25g and 0.75g CaHA/cm 3 (Bruker) were scanned the same day for calibration.
Bone histomorphometry: Bone saples were fixed and embedded in methyl-methacrylate as described (16 Tyne and Wear, UK). Plasma samples were prepared from blood collected from the orbital sinus of 23-day old pups that had been fasting for 6 hours.
PTH:
Was measured using a PTH EIA kit according to the manufacturer's instructions (Ray Biotech, Norcross, GA,USA). Plasma samples were prepared from blood collected from the orbital sinus from non-fasting 25-day old pups. 
25-(OH)-vitamin D3:
Measurement of Gastric pH
+/+ and RQ/RQ mice, between 20-30 days old and still nursing, were of both sexes and lines. Mice were fasted for two hours and then weighed and sacrificed, and stomachs were dissected from the esophagus to the pylorus and weighed. Stomach contents were then flushed with 500 microliters of unbuffered water (pH 7.8), diluted with an equal amount of water, and the pH of the mixture was measured with a pH meter.
Electron microscopy analyses
Scanning Electron microcopy (SEM): After culturing osteoclasts on bone slices for 15-17 days as described above, cells were removed with cotton swabs and 1% bleach. The bone fragments were washed thoroughly with water 3 times, with 70% ethanol twice for 20 minutes each, and then incubated in ethanol 100% overnight. The bones were then dried in a dessicator for 24 hours, mounted on aluminum stubs, sputter-coated with iridium (CCU-010, Safematic, Bad Ragaz, Switzerland), and visualized with a Zeiss Sigma 500 scanning electron microscope (Zeiss).
Transmission electron microscopy (TEM):
Bone slices carrying OCLs were fixed with 3% paraformaldehyde, 2% glutaraldehyde in 0.1 M cacodylate buffer containing 5 mM CaCl2 (pH 7.4), then postfixed in 1% osmium tetroxid, stained with 2% uranyl acetate in water, dehydrated in graded ethanol solutions and embedded in Agar 100 epoxy resin (Agar Scientific Ltd., Stanstead, UK).
Ultrathin sections (70-90 nm) were viewed and photographed with an FEI Tecnai SPIRIT transmission electron microscope (FEI, Eindhoven, The Netherlands), operated at 120 kV and equipped with an EAGLE CCD camera.
Protein blot analysis
Cells were washed once in PBS and lysed in RIPA buffer (50 mM Tris pH 8, 150 mM NaCl, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS), supplemented with protease inhibitors (1 mM N-(aaminoethyl) benzene-sulfonyl fluoride, 40 uM bestatin, 15 uM E64, 20 uM leupeptin, 15 uM pepstatin; Sigma). Protein concentrations were determined by the Bradford method using bovine serum albumin as a standard. SDS-PAGE and protein blotting were performed as described (17) . Primary antibodies used included mouse monoclonal anti-actin (Sigma) and rabbit polyclonal anti-SNX10 (Sigma). Enhanced chemiluminescence signals were visualized using an ImageQuant LAS 400 Mini instrument (GE Healhtcare Biosciences, Uppsala, Sweden) and quantified (GelPro analyzer, Media Cybernetics, Rockville, MD, USA).
Quantification of Statistical Analysis
Data were analyzed by Student's t-test or the Mann-Whitney U test as indicated. Data errors (SEM, SD)
are indicated in each Figure. Statistical analyses were performed using Prism 6 (GraphPad) or JMP13 (SAS). The level of statistical significance was set at p=0.05.
Results
Impaired growth and development in mice homozygous for the R51Q SNX10 mutation
In order to generate a pre-clinical mouse model for ARO caused by the R51Q SNX10 mutation, we mutated exon 4 of the endogenous Snx10 gene using the CRISPR technology, in mice (Fig 1A) . Two separate R51Q SNX10 mutant lines of mice were generated from independent founder mice (lines 43 and 87), and both exhibited similar phenotypes. Most of the studies below were performed in mice from line 43, with key results verified also in line 87, as indicated.
Mating of heterozygous R51Q SNX10 mice within each line yielded wild-type (+/+), heterozygous (RQ/+), and homozygous (RQ/RQ) mutant mice in near-Mendelian ratios, indicating that R51Q SNX10
does not significantly affect prenatal and early post-natal survival. Homozygous RQ/RQ mice appeared grossly normal at birth. Their weights and body lengths were similar to their wild-type and heterozygous littermates at 2 weeks of age, except for a slight decline in the weight of female RQ/RQ mice (Fig 1B) .
By the age of 4 weeks, a significant lag in both parameters became evident in RQ/RQ mice of both sexes (Figs 1B, 1C; Panel A in Fig S1) . Internal organs, such as the liver, spleen, and stomach, were smaller in RQ/RQ mice than in RQ/+ and wild-type mice, but were in proportion with the smaller size of these mice (Panel B in Fig S1 , Table S1 ). Upon physical examination, all RQ/RQ mice lacked teeth (Fig 1C) .
Histological studies revealed that molars were present but failed to erupt, and osteopetrosis was detected in most skull bones, including the maxillae and mandibles (Figs 2A, 2B ). Some RQ/RQ mice developed mandibular osteomyelitis, which involved the osteopetrotic bone and surrounding soft tissues (Fig 2B) .
Absence of functional teeth rendered RQ/RQ pups completely dependent on mother's milk for survival; yet most of these mice appeared alert and active, despite their smaller size. RQ/RQ mice were grown routinely up to the age of 6-8 weeks in the presence of lactating females, and anecdotal experience indicated that some can survive longer. Absence of teeth is characteristic of mice suffering from severely reduced OCL-mediated bone resorption (e.g., (18)), suggesting that the RQ/RQ phenotype is associated with OCL dysfunction. Heterozygous RQ/+ mice were physically indistinguishable from wild-type mice by all of the parameters described above.
Homozygous R51Q SNX10 mice exhibit massive osteopetrosis with mildly reduced bone mineral density X-ray analysis revealed markedly increased density in bones from RQ/RQ mice relative to RQ/+ and wild-type mice (Fig 2C) . In particular, femurs of RQ/RQ mice possessed the ARO "Erlenmeyer flask" shape ( Fig 2C;(19) ) that is also found in human osteopetrotic patients (3, 7) . Micro-CT analysis revealed that femurs from RQ/RQ mice were shorter, deformed, and displayed a somewhat "pockmarked" appearance at the cortical bone surface; the length and cortical mineral density of these bones were reduced (Figs 2C-E; Table S2 ). Further examination by micro-CT revealed that the femoral bone marrow cavities of RQ/RQ mice were almost completely replaced with a compact bone matrix ( Fig   3A) . In line with these observations, the bone volume, trabecular thickness and number of trabeculae per unit of bone volume were significantly increased in these samples, rendering their inter-trabecular separation less apparent (Fig 3B and Table S3 ). Similar findings were also obtained in vertebrae (Fig 3C,   Fig S2, and Table S3 ).
Histological analysis of the proximal tibia of RQ/RQ mice indicated massively increased amounts of trabecular bone, and corresponding reductions in bone marrow space ( Figs 3D, 3E, Fig S2) . Similar defects were also noted in the secondary ossification center proximal to the growth plate (Fig 3D) .
Significant regions of homozygous trabecular bone stained less strongly with hematoxylin/eosin (Fig 3E,   Fig S2) , a finding that is most likely attributable to the presence of residual, unresorbed cartilage secondary to reduced or absent OCL activity (eg. (3)). RQ/RQ mice of both sexes were affected to similar extents, and none of the above findings were observed in RQ/+ or +/+ mice. In summary, osteopetrosis in RQ/RQ mice is widespread and affects multiple bone types, including flat bones of the skull, vertebrae, and long bones such as the tibia and femur.
It is notable that whole-body SNX10 knockdown (SNX10-KD) mice suffer from a combination of massive osteopetrosis and, paradoxically, rickets (14) . While RQ/RQ mice exhibited massive osteopetrosis and their bone mineral density was somewhat reduced (Table S2) , their gastric pH, stomach appearance, and circulating levels of calcium and PTH were normal (Fig 3F, Table S1 , and Fig S3) . The stomach weights of these mice were in proportion to their body weight (Table S1) (Fig 3F) , and there are no reports of them suffering from rickets. We conclude that RQ/RQ mice suffer from massive and widespread osteopetrosis that is similar to the major clinical symptoms of ARO caused by R51Q SNX10 in humans.
Decreased OCL numbers in RQ/RQ mice
OCL numbers in bones of RQ/RQ mice were significantly reduced; fewer TRAP-positive OCLs were visible in histological samples of mutant bone (Fig 4A) , as well as when OCL numbers were quantified by bone histomorphometric analysis (Fig 4B, Table S4 ). Homozygous bone samples contained normal numbers of osteocytes ( Fig 4C, Table S4 ) but, unexpectedly, reduced numbers of osteoblasts (OBs; see Fig 4D ; Table S4 ). However, bone formation rates were normal in RQ/RQ mice (Fig 4E) , indicating that the phenotype of these mice is not due to a major bone formation defect. This conclusion is further supported by the finding that OBs derived from calvarias of +/+, RQ/+, and RQ/RQ mice exhibited similar mineralization rates in vitro (Fig S4) . Plasma levels of N-terminal type-I procollagen (P1NP), a marker of bone formation in vivo, were not distinct in RQ/RQ mice vs. controls (Fig 4F) .
Of note, RQ/RQ mice displayed elevated levels of plasma collagen type-I cross-linked Ctelopeptides (CTX) (Fig 4G) , which is used as a clinical indicator of OCL-mediated bone resorption in vivo. Elevated CTX levels contradict the massive increase in bone mass found in RQ/RQ mice by several independent methodologies, and, critically, the absent ability of RQ/RQ OCLs to degrade bone (see below). We note that CTX levels can be affected also by other parameters, such as clearance rates (20) .
Moreover, high CTX levels in vivo despite reduced OCL activity have been documented in various mouse models of OCL dysfunction as discussed further below.
RQ/RQ osteoclasts are gigantic
In humans, the cause of ARO induced by the R51Q SNX10 mutation is aberrant OCL-mediated bone resorption (6) . Absence of teeth (Fig 1C) , reduced OCL numbers in femurs (Figs 4A, 4B), and presence of massive osteopetrosis despite normal bone formation rates (Fig 4E) suggest that OCL activity is reduced in RQ/RQ mice in vivo. The significant reduction in the bone marrow volume in RQ/RQ mice led us to generate OCLs in vitro by culturing primary splenocytes in the presence of M-CSF and RANKL. Cells from RQ/RQ mice adhered to bone and grew rapidly, fusing to form massive multinuclear cells that were dramatically larger than similar cells from +/+ or from RQ/+ mice ( Figs   5A , 5B, 5D). These large RQ/RQ OCLs stained positively for TRAP, but staining was less intense and more diffuse than that seen in wild-type or RQ/+ cells (Fig 5A) . RQ/RQ OCLs grown on bone grew, and then fused and died before their matched +/+ and RQ/+ counterparts (Fig 5A) . RQ/RQ OCLs each exhibited a single sealing zone structure that demarcated the entire periphery of the cell, in proportion with its size, in contrast to the much smaller sealing zone structures of +/+ and RQ/+ OCLs (Fig 5B) .
In order to compare their bone resorptive capacity, we seeded +/+, RQ/+, and RQ/RQ splenocytes on fragments of bovine bone and grew them for 15 days in the presence of M-CSF and RANKL. Cells from all three genotypes grew well and fused as indicated in Fig 5A. We then removed the cells and examined the formation of resorption pits on the bone surface, which indicate OCL activity, by scanning electron microscopy (SEM). As seen in Fig 5C, OCLs from +/+ and RQ/+ mice readily formed resorption pits that were similar in size and in appearance. In contrast, RQ/RQ OCLs did not form pits at all, indicating they are severely deficient in function. Since the pit resorption assay provides an accumulated record of resorption activity throughout the life of the culture, these results also indicate that the RQ/RQ cells were at no time capable of significant activity.
Measurements of the areas of individual OCLs grown on bone fragments indicated that the average size of RQ/RQ OCLs was 14.6 times larger than +/+ OCLs; this ratio increased to 49 when the largest 5% of cells of each genotype were compared (Fig 5D) . RQ/RQ cultures contained a significant number of cells that reached sizes more than 100-fold larger than the average +/+ OCL (Fig 5D) . No cells of similar size were observed in +/+ or RQ/+ cultures.
We next examined if the R51Q mutation affects expression of the SNX10 protein in vivo.
Protein blots prepared from mouse OCLs revealed that the SNX10 protein is expressed at relatively low levels in macrophages produced following M-CSF treatment of splenocytes, but its expression is significantly increased upon RANKL-induced differentiation of these cells into OCLs. This expression pattern is observed in +/+, RQ/+, and RQ/RQ cells (Fig 5E) . OCLs from mice of the three genotypes express similar levels of the SNX10 protein (Fig 5E) , indicating that the R51Q mutation does not affect overall SNX10 protein levels. Importantly, +/+ OCLs express wild-type Snx10 mRNA, and RQ/RQ OCLs express mutant mRNA exclusively; OCLs from RQ/+ mice express both Snx10 mRNA species (Fig S5) . Taken together, the expression of mutant SNX 10 RQ/RQ in maturing osteoclasts leads to apparently deregulated fusion and increased size of osteoclasts.
RQ/RQ osteoclasts exhibit abnormal ruffled borders and are severely functionally impaired
We next examined the structure of RQ/RQ OCLs grown on bone in vitro by transmission electron microcopy (TEM). Ruffled borders, the basal membranal structures through which the cells secrete acid and proteases onto the bone surface below, were present in all +/+ and RQ/+ cells, visible as areas in which heavily convoluted membranous folds extended from the ventral aspect of the cells onto and into the bone surface below (Fig 6A) . In contrast, RQ/RQ OCLs lacked ruffled border structures. Some cells did not appear to make contact with bone, while others made contact with bone via a nearly flat surface that completely lacked the convoluted structure of the ruffled border membranes (Fig 6A) . TEM was also used to examine the structure of endogenous OCLs in femurs of +/+ and RQ/RQ mice. Here, too, convoluted membranal structures typical of ruffled borders were observed in +/+ cells (Fig 6B) , while RQ/RQ OCLs lacked ruffled borders or made contact with the underlying bone surface through surfaces that did not resemble the ruffled border seen in +/+ cells (Fig 6B) . Our results indicate that the massive osteopetrosis of R51Q SNX10 mice arises from virtual lack of OCL-mediated bone resorption that is caused by absent or dysfunctional ruffled border structures.
Discussion
Autosomal recessive osteopetrosis is a lethal genetic disease, whose main symptoms are caused by OCL dysfunction. The only treatment currently available for ARO is hematopoietic stem cell transplantation (HCST), which enables production of healthy and functional OCLs that restore bone resorbing abilities and prevent further bone-associated symptoms. HSCT is a difficult procedure, and is offered in cases where all of the patient's symptoms are caused by OCL dysfunction. This typically precludes HCST as a treatment for patients whose underlying mutation causes significant additional, eg.
neurological, complications (3, 21, 22) . Moreover, HCST does not reverse all the damage caused by absent bone resorption, such as losses of hearing and vision that are caused by closure of skull foramina.
These facts, together with the rare occurrence of ARO and its heterogeneous genetic basis, make development of accurate mouse model systems for ARO essential to clarify its cellular and molecular underpinnings, and to provide alternative approaches for diagnosis and therapy.
In order to further these goals we have produced mice that carry the R51Q mutation in SNX10, the first mutation in SNX10 suggested to cause ARO in humans (6) . Homozygous R51Q SNX10 mice exhibit multiple phenotypes that are present also in humans suffering from ARO. A key feature among these is massive, early-onset, and widespread osteopetrosis that is caused by dysfunctional OCLs.
Additional similarities include the "Erlenmeyer flask" shape of the distal femoral metaphysis, dental defects (missing and impacted teeth), occasional osteomyelitis, stunted growth, failure to thrive, and a significantly reduced lifespan (3, 21, 22) . Hepatosplenomegaly and anemia, which often develop in ARO patients, were not found in RQ/RQ mice, possibly due to their short lifespan that precludes development of these symptoms. These findings confirm the R51Q mutation in SNX10 as a causative factor in ARO.
A prominent feature of RQ/RQ OCLs is their size; these cells grow to become dramatically larger than wild-type OCLs, which are large cells in their own right. The size phenotype is likely cellautonomous since it is detected after several days of differentiation ex vivo in culture, and occurs irrespective of the tissue origin of the OCL precursor cells or of their growth surface. The mechanism underlying this phenotype remains unclear but might include, for example, increased fusion of precursor cells or excess spreading and flattening of the multi-nuclear fusion products. Importantly, these findings indicate that the enigmatic mechanism that regulates OCL size is actively regulated by cellular-genetic mechanisms, in which SNX10 plays a central role and which is disrupted by the R51Q mutation.
Another striking feature of RQ/RQ OCLs is their inability to resorb bone ex vivo, a finding that accounts for the massive osteopetrosis of RQ/RQ mice. The inability of RQ/RQ OCLs to resorb bone is most likely the result of structurally-defective or absent ruffled borders, which are essential for proper OCL activity. Ruffled borders are composed of large, elaborate membranal folds that emanate from the ventral side of the cell. SNX10 and other SNX family members participate in the sorting of cellular vesicles, a process that involves cellular membranes and can affect their structure. It is possible that the R51Q SNX10 mutation disrupts membranal sorting in a manner that prevents proper development and function of the ruffled border. The large size of RQ/RQ OCLs may also contribute to their loss of function.
For example, the strikingly larger size of the sealing zone structures of RQ/RQ OCLs (Fig 5B) may make it difficult to isolate a particular area of bone surface, prior to its intended degradation. The large size of RQ/RQ OCLs may also diminish their survival, in agreement with their increased fragility and significantly shorter lifespan in vitro ( Fig 5A) and with their reduced numbers in vivo (Fig 4A, 4B ).
Serum CTX levels, which are considered a clinical indicator of OCL-mediated bone resorption in vivo, are elevated in RQ/RQ mice. This finding appears to contradict the documented inactivity of RQ/RQ OCLs and the massively increased bone mass of these mice in the presence of normal bone formation rates. However, serum CTX levels in osteopetrotic mouse models vary considerably, from reduced (e.g., in mice lacking RANKL (23) or Rac (24)), through unchanged (e.g., mice lacking Src, (23)) to increased (e.g., mice lacking CLCN-7 (25) or in SNX10-KD mice (14)). In cases of osteoclast-rich disease, minimal resorptive activity of OCLs coupled with their high absolute numbers, such as in CLCN-7-deficient mice (25) , have been suggested to account for elevated CTX levels. However, RQ/RQ mice contain fewer OCLs per unit surface area of bone, arguing against the validity of this explanation in this case. High CTX levels might also be caused by disruption of processes unrelated to bone, such as increased stability of CTX peptides or their reduced clearance rates from the circulation (20) .
Two major types of ARO have been described in humans and in mouse models for this disease: OCLpoor ARO, which is caused by mutations in gene products that are essential for production of OCLs, and OCL-rich disease, in which normal or increased amounts of functionally-impaired OCLs are present due to mutations that affect vesicle trafficking and ruffled border formation, but not cell production or survival (3). The R51Q SNX10 mutation defines a third category, in which OCLs are both non-functional and their amount is significantly reduced in vivo. We believe that the basis for this unique phenotypic combination are the dual consequences of the R51Q mutation in SNX10, which renders the cells inactive while increasing their size to a degree that reduces their survival in vivo.
SNX10-KD mice have also been proposed as a model for ARO (14) . While osteopetrosis and other major parts of the RQ/RQ phenotype are also found in SNX10-KD mice, significant differences exist between these models. The SNX10-KD mouse phenotype is characterized by an increased mass of bone that exhibits, paradoxically, markedly reduced mineral content (14) . This rachitic phenotype is likely due to disruption of SNX10 function in the stomach that leads to higher gastric pH, abnormal stomach appearance, and reduced absorption of dietary calcium (14) . The femoral mineral content of RQ/RQ mice is reduced, but to a lesser degree than that seen in SNX10-KD mice. Moreover, the main defects that give rise to the rachitic phenotype of SNX10-KD mice do not exist in RQ/RQ mice: stomach appearance and gastric pH are normal, as are serum levels of PTH and, critically, calcium. The somewhat decreased mineral density in RQ/RQ bones is therefore not caused by decreased bioavailability of dietary calcium, but might be due to the reduced levels of vitamin D3 in circulation that likely arise by an unrelated mechanism. We note that normal concentrations of circulating calcium were reported in humans suffering from ARO induced by R51Q SNX10 (Fig 3F) and by the Vasterbotten frameshift mutation in SNX10 [10] ; rickets symptoms were not reported in these cases (6, 7) . Administering calcium gluconate, which bypassed reduced calcium resorption in the SNX10-KD mice and resolved their rachitic phenotype (14), is therefore not a general treatment for all forms of SNX10-based ARO, and its potential benefit most likely depends on the identity of the SNX10 mutation at hand.
OCLs two to five times larger than controls have been reported in cultures prepared from blood monocytes of patients of the genetically-distinct SNX10 Vasterbotten variant of ARO (7), and in mice lacking OSTM-1 (26) that model another cause of ARO. We note that large OCLs were not described in mice carrying whole-body or OCL-specific knockdowns of SNX10 (14) . Since knockdown efficiency in the latter SNX10 models was high but nonetheless not complete, it is possible that residual amounts of WT SNX10 protein were sufficient to maintain normal OCL sizes. Alternatively, the size differences between R51Q SNX10 and SNX10-KD OCLs may reflect a true distinction between the consequences of reduced expression of wild-type SNX10 vs. normal expression levels of its R51Q mutant. In either case, these size differences provide further indication that different mutations in SNX10 can result in distinct phenotypes.
Data presented in this study indicate that the osteopetrotic phenotype of RQ/RQ mice is caused by a significant loss of function by OCLs. It is, however, less clear how the R51Q mutation affects the as-yet unknown biochemical functions of the SNX10 protein within these cells. RQ/+ mice that are heterozygous for the R51Q SNX10 mutation are indistinguishable from +/+ mice. This fact, together with the normal size, ruffled border morphology, and ex-vivo resorbing activity of RQ/+ OCLs indicates that heterozygosity for R51Q SNX10 does not elicit OCL or bone phenotypes. It is therefore highly unlikely that the R51Q SNX10 mutant protein acts through a dominant gain-of-function mechanism. It possible that R51Q SNX10 acts by a loss-of-function mechanism, or by a gain-of-function mechanism that becomes evident only in the absence of the wild-type protein. The former explanation is challenged by the differences between the R51Q SNX10 and SNX10 knockdown (SNX10-KD) mouse models at the whole-animal and cellular levels that were described above.
Multiple mutations in SNX10 have now been described in ARO (6) (7) (8) . Our study underscores the importance of mimicking the human mutations as closely as possible in preclinical models, since lossof-function approaches do not necessarily generate the complex phenotypes seen at the cellular level and prevent examination of possible gain-of-function effects of these mutations. By presenting one of the first knock-in models for ARO, we accomplish this aim for the SNX10 R51Q mutation and establish a valuable tool for uncovering mechanisms of this genetic disorder for the future development of more effective therapeutic strategies.
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